HLA-G/LILRBs: A Cancer Immunotherapy Challenge

• Published in: Trends in cancer Vol. 7; no. 5; p. 389
• Main Authors: Carosella, Edgardo D, Gregori, Silvia, Tronik-Le Roux, Diana
• Format: Journal Article
• Language: English
• Published: United States 01.05.2021
• Subjects: Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Antigens, CD - metabolism; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - metabolism; Drug Synergism; HLA-G Antigens - metabolism; Humans; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immune Checkpoint Proteins - metabolism; Immunotherapy, Adoptive - methods; Leukocyte Immunoglobulin-like Receptor B1 - antagonists & inhibitors; Leukocyte Immunoglobulin-like Receptor B1 - metabolism; Lymphocytes, Tumor-Infiltrating - drug effects; Lymphocytes, Tumor-Infiltrating - immunology; Lymphocytes, Tumor-Infiltrating - metabolism; Membrane Glycoproteins - antagonists & inhibitors; Membrane Glycoproteins - metabolism; Neoplasms - immunology; Neoplasms - therapy; Receptors, Chimeric Antigen - immunology; Receptors, Immunologic - antagonists & inhibitors; Receptors, Immunologic - metabolism; Tumor Escape; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology; vascular targeting; HLA-G; vascular endothelial growth factor; LILRB1/2; cancer immunotherapy; immune checkpoints
• ISSN: 2405-8025
• DOI: 10.1016/j.trecan.2021.01.004

Despite some success, many patients do not benefit from immunotherapy. New strategies to improve clinical efficacy include identification of novel immune-checkpoint (IC) targets or a combination of immunotherapy with antiangiogenic treatments. Here, we propose the therapeutic use of IC, HLA-G/LILRB, and explore its enhanced synergistic antitumor activity when combined with antiangiogenic therapies.